Table 1.

Clinicopathologic characteristics of TNBC patients according to the integrated RNA signatures in two sets

Training setValidation set
mRNA signaturemRNA–lncRNA signaturemRNA signaturemRNA–lncRNA signature
CharacteristicsNHigh risk (%)Low risk (%)High risk (%)Low risk (%)NHigh risk (%)Low risk (%)High risk (%)Low risk (%)
Age, y
 Median555056505653.553.553.55453
 IQR46–6143–5849.8–6243–5949–61.344.8–5945.5–58.344.8–60.346.5–5944–59
 ≤506838 (55.9)30 (44.1)34 (50.0)34 (50.0)3919 (48.7)20 (51.3)20 (51.3)19 (48.7)
 >509731 (32.3)66 (68.8)31 (32.3)66 (68.8)6226 (41.9)36 (58.1)32 (51.6)30 (48.4)
Menopause
 Yes10137 (36.6)64 (63.4)35 (34.7)66 (65.3)6426 (40.6)38 (59.4)31 (48.4)33 (51.6)
 No6432 (50.0)32 (50.0)30 (46.9)34 (53.1)3214 (43.8)18 (56.3)16 (50.0)16 (50.0)
 Unknown00 (0.0)0 (0.0)0 (0.0)0 (0.0)55 (100.0)0 (0.0)5 (100.0)0 (0.0)
Tumor size, cm
 ≤25823 (39.7)35 (60.3)19 (32.8)39 (67.2)3617 (47.2)19 (52.8)19 (52.8)17 (47.2)
 >210444 (42.3)60 (57.7)45 (43.3)59 (56.7)6528 (43.1)37 (56.9)33 (50.8)32 (49.2)
 Unknown32 (66.7)1 (33.3)1 (33.3)2 (66.7)00 (0.0)0 (0.0)0 (0.0)0 (0.0)
Tumor grade
 I–II329 (28.1)23 (71.9)10 (31.3)22 (68.8)3115 (48.4)16 (51.6)18 (58.1)13 (41.9)
 III10448 (46.2)56 (53.8)45 (43.3)59 (56.7)7030 (42.9)40 (57.1)34 (48.6)36 (51.4)
 Unknown2912 (41.4)17 (58.6)10 (34.5)19 (65.5)00 (0.0)0 (0.0)0 (0.0)0 (0.0)
Positive LNs
 ≤311547 (40.9)68 (59.1)44 (38.3)71 (61.7)8238 (46.3)44 (53.7)44 (53.7)38 (46.3)
 >35022 (44.0)28 (56.0)21 (42.0)29 (58.0)197 (36.8)12 (63.2)8 (42.1)11 (57.9)
Chemotherapy
 Taxane12452 (41.9)72 (58.1)48 (38.7)76 (61.3)6629 (43.9)37 (56.1)34 (51.5)32 (48.5)
 Non-taxane2712 (44.4)15 (55.6)12 (44.4)15 (55.6)3516 (45.7)19 (54.3)18 (51.4)17 (48.6)
 Unknown145 (35.7)9 (64.3)5 (35.7)9 (64.3)00 (0.0)0 (0.0)0 (0.0)0 (0.0)
Radiotherapy
 Yes5023 (46.0)27 (54.0)21 (42.0)29 (58.0)3919 (48.7)20 (51.3)21 (53.8)18 (46.2)
 No10341 (39.8)62 (60.2)41 (39.8)62 (60.2)4218 (42.9)24 (57.1)21 (50.0)21 (50.0)
 Unknown125 (41.7)7 (58.3)3 (25.0)9 (75.0)208 (40.0)12 (60.0)10 (50.0)10 (50.0)
Follow-up time, mo
 Median13.912.614.211.714.318.518.518.31819.2
 IQR8.6–21.18.4–19.39.3–22.28.2–18.49.5–22.615–26.213.6–26.115.1–26.513.7–25.715.2–27.5
RFS event2217517597281

Abbreviations: IQR, interquartile range; LN, lymph node; mo, months; RFS, recurrence-free survival; y, year.